Migdal Insurance & Financial Holdings Ltd. Blueprint Medicines Corp Transaction History

Migdal Insurance & Financial Holdings Ltd.

$6.18 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 04, 2021	SELL	$82.78 - $101.0 $559,427 - $682,558	-6,758 Closed	0 $0
Q1 2021 May 04, 2021	BUY	$90.71 - $108.28 $380,437 - $454,126	4,194 Added 163.57%	6,758 $657,000
Q4 2020 Feb 08, 2021	BUY	$92.08 - $124.48 $236,093 - $319,166	2,564 New	2,564 $288,000

Others Institutions Holding BPMC

# of Institutions

351

Shares Held

60.3M

Call Options Held

2.25M

Put Options Held

1.18M

Vanguard Group Inc Valley Forge, PA

6.68M
Shares

$605 Million
0.01% of portfolio
Black Rock Inc. New York, NY

6.65M
Shares

$601 Million
0.02% of portfolio
Price T Rowe Associates Inc Baltimore, MD

5.39M
Shares

$487 Million
0.06% of portfolio
Wellington Management Group LLP Boston, MA

3.96M
Shares

$359 Million
0.07% of portfolio
State Street Corp Boston, MA

2.77M
Shares

$250 Million
0.01% of portfolio

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account